semaglutide murietta FBI warns about counterfeit weight

This was the first demonstration that a GLP-1R agonist produces cardiovascular benefit independent of glycaemic effects, expanding the research interest in GLP-1R agonism beyond metabolic and weight endpoints

While assessing BMI is an important first step, treatment decisions always involve thorough discussions with each patient to ensure that recommended therapies align with their unique health needs, goals, and preferences

If unsure if stopping or continuing is the right option, a healthcare provider may recommend a lower dose with the potential to taper off in the future

Semaglutide was superior to placebo in terms of the trials primary endpoint, mean percentage change in BMI at week 68 (16.1% decrease vs 0.6% increase)

Medication handling and safety are essential